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Agomelatine Is Effective in Reducing Insomnia in Abstinent
Alcohol-Dependent Patients
Martin Grosshans, MD,* Jochen Mutschler, MD,† Mathias Luderer, MD,* Karl Mann, MD,*
and Kiefer Falk, MD*
Objectives: Sleep disorders are a widespread, persistent problem among
alcohol-dependent patients and have been implicated in an increased risk
for alcohol relapse. The melatonin-agonist agomelatine has been shown
to improve overall sleep quality without daytime sedation.
Methods: In an off-label therapeutic setting, 9 alcohol-dependent patients
with chronic sleep disorders received nightly doses of between 25 and 50mg
of agomelatine.
Results: After 6 weeks of agomelatine treatment, the Pittsburgh Sleep
Quality Index global score for all patients had decreased signiﬁcantly
from a mean (SD) of 13.1 (1.7) to 7.8 (1.7) (t = 12.8; P = 0.00).
Conclusions: Agomelatine is a preparation that is not prone to abuse.
The current pilot investigation shows that agomelatine might offer the
prospect of becoming a valuable addition to the pharmacological reper-
toire for the treatment of alcohol-dependence–associated insomnia.
Key Words: alcohol dependence, insomnia, abstinence, agomelatine
(Clin Neuropharm 2014;37: 00–00)
Among abstinent alcohol-dependent (AD) patients, sleepdisorders are a widespread and persistent problem and have
been associated with the risk for alcohol relapse.1 Polysom-
nographic characteristics of AD patients include prolonged
sleep latency and decreased sleep efﬁciency.2 Abstinent AD
patients also show abnormal evening melatonin proﬁles, includ-
ing a peak delay of up to 90 minutes.3 Although there is a com-
prehensive pharmacological repertoire for the treatment of
insomnia, a history of AD signiﬁcantly limits available options.
Benzodiazepines are efﬁcacious but should be considered as
contraindicated because of their potential for abuse, overdose,
and toxicity in combination with alcohol.4 Antidepressant
medications with sedative properties such as amitriptyline and
doxepin have increasingly been used to treat insomnia5 but are
often lethal when taken as an overdose and/or in combination
with alcohol and can induce sexual dysfunction. Mirtazapine
also has sedative effects, but weight gain and/or impaired sexual
function can lead to incompliance.6 In addition, several anticon-
vulsant drugs (such as carbamazepine and gabapentin) have
sedative effects and the therapeutic potential to aid sleep.7 How-
ever, carbamazepine requires blood monitoring and is associated
with hepatotoxicity, whereas gabapentin has been associated with
an increased risk for suicide.8 Other options include antipsychotic
agents such as olanzapine that have known sedative effects, but
again, associated sexual dysfunction and/or weight gain often re-
sult in incompliance.9
Agomelatine is a structural analog of melatonin and acts both
as an agonist of the MT1 and MT2 receptors as well as an antag-
onist of 5-HT2C. As such, agomelatine represents a new class
of antidepressant and was approved for the treatment of major
depression in 2009.10 Because of its mechanism of action on mel-
atonin receptors, agomelatine improves overall sleep quality with-
out daytime sedation.11,12 This effect is paralleled by changes in
sleep electroencephalograms and indicates improvements in over-
all sleep architecture.12 Furthermore, agomelatine was signiﬁcantly
less likely to cause sexual dysfunction in comparison with either
paroxetine13 or venlafaxine14 and was not associated with weight
gain or loss.15 Together, these factors indicate that agomelatine is
potentially a valuable new addition to current treatment options
for insomnia in AD patients.
A well-known weakness of randomized controlled premar-
keting trials is the exclusion of patients with addiction disorders,
resulting in a frequent lack of relevant naturalistic data on newly
approved substances. The purposes of this retrospective case anal-
ysis were therefore to determine whether agomelatine was well
tolerated and to examine the effect of agomelatine on sleep quality
in abstinent AD patients with chronic sleep disorders. To our
knowledge, this is the ﬁrst naturalistic investigation of the rela-
tionship of agomelatine to sleep quality in AD.
METHODS
Participants
The sample consisted of 8 male and 1 female (outpatient)
AD patients with persistent insomnia but without depression.
All patients had no depression (mean HAMD-21 score, <10)
or other psychiatric (except nicotine dependence) or neurologi-
cal illnesses. The mean (SD) age of the participants was 47.2
(11.2) years, with a mean (SD) duration of AD of 20 (8.3) years.
Before the current treatment, several patients were weaned off
known sleep-promoting substances either because of their poten-
tial for abuse (benzodiazepines) or because they were not well tol-
erated, including impairment of sexual function and/or weight
gain and/or daytime sedation (antidepressants, antipsychotics).
Because most patients exhibited long-term AD, 7 of 9 patients re-
ceived either disulﬁram (1500 mg/wk) or naltrexone (50 mg/d) to
prevent relapse.
Because agomelatine is potentially hepatotoxic, it was only
prescribed in patients who fulﬁlled the following preconditions:
(1) patients well known to our department with a proven history
of reliability and timely and regular presentation, (2) patients
who were comprehensively informed of the potential hepatotox-
icity of agomelatine, particularly in combination with alcohol
intake, and showed understanding of the necessity to rapidly re-
duce and cease agomelatine use in case of a relapse, (3) patients
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with no known liver diseases, and (4) patients who consented to
repeated laboratory blood analyses before and during treatment.
Agomelatine Treatment
The study commenced with nightly oral doses of 25 mg in
all patients. After 3 weeks, all patients were revisited and, in 6 of
9 patients, the dosage of agomelatine was increased to 50 mg/d
because of its only partial effectiveness on sleep quality.
Assessment of Sleep Quality
Sleep quality was assessed using the Pittsburgh Sleep
Quality Index (PSQI) before (T1) and after 6 weeks of treatment
(T2) with agomelatine. The PSQI is a self-rated questionnaire
that assesses sleep quality and disturbances. Nineteen individual
items generate 7 “component” scores: subjective sleep quality,
sleep latency, sleep duration, habitual sleep efﬁciency, sleep
disturbances, use of sleep medication, and daytime dysfunction.
The sum of scores for these 7 components yields 1 global score.
Laboratory Analysis
Before (T1) and during treatment with agomelatine (T2),
all patients were monitored for serum levels of the liver enzymes
γ-glutamyltransferase (GGT), alanine transaminase (ALT), and
aspartate transaminase (AST).
Statistics
Statistical Package for the Social Sciences 16.0 (SPSS Inc,
Chicago, Ill) was used for the statistical analyses. To compare
PSQI scores and laboratory values before and after 6 weeks of
treatment, 1 sample t test was performed. The level of signiﬁ-
cance was set at α < 0.05. Mean data values are presented, to-
gether with standard errors of the mean.
RESULTS
Sleep Quality
All patients in our sample initially scored higher than 10
(mean [SD], 13.1 [1.7]) on the PSQI global score, indicating se-
vere insomnia. After 6 weeks of agomelatine treatment, the
PSQI global score for all patients had decreased signiﬁcantly,
to a mean (SD) of 7.8 (1.7) (t = 12.8; P = 0.00), (Table 1).
Laboratory Analyses
Hepatotoxicity of agomelatine, as appraised by serum
levels of 3 liver enzymes, was not evident at the doses used in
this study (Table 1).
Sexual Dysfunction and Weight Gain
Although we did not operationalize sexual functions, no
decrease of sexual desire, erectile dysfunction, and/or orgasm
disorders were reported by any of the participants after 6 weeks.
Furthermore, no weight gain or other drug-related adverse ef-
fects were observed.
DISCUSSION
The present retrospective data suggest that agomelatine
may improve the sleep quality of male AD patients with chronic
AD-associated insomnia. As expected, adverse effects such as
weight gain or sexual dysfunction were not observed during
6 weeks of treatment. Thus, agomelatine was well tolerated
and all patients expressed their desire to continue the treatment
under the conditions described previously.
However, post–marketing experience with agomelatine has
demonstrated that one adverse effect is a possible increase in se-
rum levels of liver enzymes. This led to a recommendation by
the European Medicines Agency for liver function tests as a pre-
cautionary measure at the onset of treatment, then periodically
at 6 and 12 weeks as well as 12 months, and, thereafter, when
clinically indicated.16 In addition, it should be noted that
agomelatine is contraindicated in patients with hepatic impair-
ment such as cirrhosis. Thus, in light of the possible liver toxic-
ity of agomelatine in a population already vulnerable to liver
disease per se, we strongly recommend that agomelatine be pre-
scribed only to those AD patients who fulﬁll the criteria deﬁned
by us previously.
An important limitation in the present study is that most of
the included patients have long-term alcoholism who are receiv-
ing treatment with disulﬁram. Because disulﬁram treatment
triggers the formation of tryptophol, a compound that induces
sleep,17 the presence of this compound may inﬂuence the as-
sessment of the sleep-inducing effect of agomelatine in AD.
Furthermore, it is important to mention that, in general, retro-
spective case series with the absence of control groups provide
only weak statistical evidence and can be prone to bias. On the
other hand, case series can generate new hypotheses or possible
TABLE 1. Patients Characterized by Age and Sex
Age, y, Sex Dosage, mg PSQI (T1) PSQI (T2) GGT (T1) GGT (T2) AST (T1) AST (T2) ALT (T1) ALT (T2)
49 (m) 25 12 8 38 19 22 19 41 19
57 (m) 50 14 7 21 18 18 23 13 17
58 (m) 50 11 5 18 39 17 20 10 14
45 (m) 25 13 8 23 15 60 27 42 22
43 (m) 50 11 7 30 27 23 27 28 24
65 (m) 50 16 11 26 24 33 41 34 33
43 (m) 50 12 9 30 28 31 30 29 21
33 (m) 50 15 8 31 33 37 36 55 47
32 (f ) 25 14 9 58 23 28 24 28 13
Mean (SD) — 13.1 (1.7) 7.8 (1.7)* 30.5 (3.9) 25.0 (3.2)* 29.8 (4.3) 27.5 (3.1)* 31.1 (4.7) 28.1 (7.0)*
Agomelatine dosage after 6 weeks.
Sleep quality and liver enzymes (U/L) before (T1) and after 6 weeks (T2).
*The statistical signiﬁcance between the means of T1 and T2 (P < 0.01).
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new treatment options that can be later tested under controlled
conditions. In conclusion, agomelatine is a preparation that is
not prone to abuse, shows a robust decrease in PSQI global
score in AD patients, and now offers the prospect of becoming
a valuable addition to the pharmacological repertoire for the
treatment of AD-associated insomnia. To corroborate and ex-
tend our current data, we strongly recommend the further as-
sessment in large controlled clinical trials.
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